Pre-made Briakinumab benchmark antibody ( Whole mAb, anti-IL12B therapeutic antibody, Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-081
Pre-Made Briakinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Briakinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Preregistration (w)|
|100% SI Structure||5n2k:LK:BA:PO:DC:NM:FE|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Cambridge Antibody Technology;Abbott GmbH & Co. KG|
|Conditions Discontinued||Plaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis|